+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Systemic Drug Delivery Strategies

  • ID: 5308649
  • Book
  • September 2021
  • 625 Pages
  • Elsevier Science and Technology
1 of 3
Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 examines the challenges of delivering immuno-oncology therapies, focusing specifically on the multiple technologies of affective drug delivery strategies. Immuno-oncology (IO) is a growing field of medicine at the interface of immunology and cancer biology leading to development of novel therapeutic approaches, such as chimeric antigen receptor T-cell (CAR-T) and immune checkpoint blockade antibodies, that are clinically approved approaches for cancer therapy. Although currently approved IO approaches have shown tremendous promise for select types of cancers, broad application of IO strategies could even further improve the clinical success, especially for diseases such as pancreatic cancer, brain tumors where the success of IO so far has been limited. This volume of Delivery Strategies and Engineering Technologies in Cancer Immunotherapy discusses methods of targeting tumors, CRISPR technology, and vaccine delivery among many other delivery strategies.

Systemic Drug Delivery Strategies: Delivery Strategies and Engineering Technologies in Cancer Immunotherapy, Volume 2 creates a comprehensive treaty that engages the scientific and medical community who are involved in the challenges of immunology, cancer biology, and therapeutics with possible solutions from the nanotechnology and drug delivery side.

- Comprehensive treaty covering all aspects of immuno-oncology (IO)- Novel strategies for delivery of IO therapeutics and vaccines- Forecasting on the future of nanotechnology and drug delivery for IO
Note: Product cover images may vary from those shown
2 of 3

1. Delivery strategies for immune checkpoint blockade inhibitors 2. Delivery strategies for ex vivo and in vivo T-cell reprogramming 3. Delivery strategies for ex vivo and in vivo NK cell reprogramming 4. Delivery strategies for tumor-associated macrophage reprogramming 5. Reprogramming lymphocytes for tumor immunotherapy 6. Targeting tumor-associated neutrophils in immunotherapy 7. Targeting tumor-associated fibroblast in immunotherapy 8. Oncolytic viral particle delivery 9. Extracellular vesicles (exosomes) in tumor immunotherapy 10. Nucleic acid-based delivery and reprogramming for tumor immuno-oncology 11. CRISPR-based gene editing in cancer immunotherapy 12. Delivery strategies for glioma immunotherapy 13. Delivery strategies for STING agonists 14. Delivery strategies for cancer vaccine and immunoadjuvant 15. Targeted delivery and reprogramming myeloid-derived suppressor cells (MDSC) in cancer 16. Delivery of radio-immunotherapy for solid tumors 17. Delivery of photo-immunotherapy for cancer 18. Local immunotherapy of cancer and metastasis 19. Delivery strategies to overcome tumor immunotherapy resistance

Note: Product cover images may vary from those shown
3 of 3
Amiji, Mansoor M.
Mansoor M. Amiji is the Distinguished Professor and Chairman of the Department of Pharmaceutical Sciences at the Bouvé College of Health Sciences at Northeastern University. Dr. Amiji has edited a number of books and is a frequently published author. His research focuses on the synthesis of novel polymeric materials for medical and pharmaceutical applications, drug delivery systems and nanomedical technologies, and his contributions in research advising, grant reviews for various organizations and editorial work for journals are invaluable.
Milane, Lara Scheherazade
Dr. Lara Milane is Assistant Teaching Professor in Biotechnology at the Bouvé College of Health Sciences at Northeastern University. She is interested in Mitochondrial Medicine. She is working on developing nanomedicines for a range of diseases (cancer, neurodegenerative disease, aging) that manipulate mitochondria for therapeutic outcomes. Dr. Milane was trained as a National Cancer Institute/ National Science Foundation Nanomedicine Fellow at Northeastern University, Boston, MA. Dr. Milane is an intuitive cancer biologist with research interests in developing translational nanomedicines that exploit the hallmarks of cancer.
Note: Product cover images may vary from those shown
Adroll
adroll